Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

InMed Pharmaceuticals  / Equity Bottom-Up

<ul><li>InMed completes the screening process in its neurodegenerative diseases program.</li><li>InMed took a significant step forward in its INM-900 series program after confirming that it has made its final selection of a lead Alzheimer’s disease drug candidate.</li><li>InMed launched the program in November 2022, targeting the use of proprietary cannabinoid analogs to treat neurodegenerative diseases after its research had identified two promising cannabinoid analog candidates warranting further investigation in in vivo studies.</li></ul>

InMed completes the screening process in its neurodegenerative diseases program.InMed took a significant step forward in its INM-900 series program after confirming that it has made its final selection of a lead Alzheimer’s disease drug candidate.InMed launched the program in November 2022, targeting the use of proprietary cannabinoid analogs to treat neurodegenerative diseases after its research had identified two promising cannabinoid analog candidates warranting further investigation in in vivo studies.

InMed Pharmaceuticals Inc - Unveiling INM-901

<div><div><div><ul><li>BayMedica continues impressive growth. As had already been signaled in an early disclosure filing in July, InMed’s BayMedica subsidiary delivered $2.3 million of revenue for the final quarter of its fiscal year ended June 30, 2023.</li><li>This represents 124% sequential revenue growth over the preceding quarter following sequential revenue growth of 46% and 120% recorded for 2QFY23 and 3QFY23, respectively.</li><li>The full fiscal year 2023 revenue total exceeded $4.1 million.</li></ul></div></div></div>

BayMedica continues impressive growth. As had already been signaled in an early disclosure filing in July, InMed’s BayMedica subsidiary delivered $2.3 million of revenue for the final quarter of its fiscal year ended June 30, 2023.This represents 124% sequential revenue growth over the preceding quarter following sequential revenue growth of 46% and 120% recorded for 2QFY23 and 3QFY23, respectively.The full fiscal year 2023 revenue total exceeded $4.1 million.

InMed Pharmaceuticals, Inc. - 4QFY23 Review; Progress on All Fronts

<ul style="list-style-type: disc;"><li><p>Therapeutic attributes of CBC highlighted in white paper. InMed Pharmaceuticals’ commercial subsidiary BayMedica released a white paper, which collates a curated collection of scientific research on the physiological and potential therapeutic effects of cannabichromene (CBC).</p></li><li><p>CBC is BayMedica’s lead product sold to the health &amp; wellness sector.</p></li><li><p>CBC demonstrates potent anti-inflammatory effects. Since the discovery of the endocannabinoid system (ES) in 1988, there has been mounting research into the interaction of cannabinoids with ES receptors, which regulate critical human functions, such as temperature, appetite, blood sugar, sleep, memory, emotional processing, pain, and inflammatory and immune responses. </p></li></ul>

Therapeutic attributes of CBC highlighted in white paper. InMed Pharmaceuticals’ commercial subsidiary BayMedica released a white paper, which collates a curated collection of scientific research on the physiological and potential therapeutic effects of cannabichromene (CBC).CBC is BayMedica’s lead product sold to the health &amp; wellness sector.CBC demonstrates potent anti-inflammatory effects. Since the discovery of the endocannabinoid system (ES) in 1988, there has been mounting research into the interaction of cannabinoids with ES receptors, which regulate critical human functions, such as temperature, appetite, blood sugar, sleep, memory, emotional processing, pain, and inflammatory and immune responses. 

InMed Pharmaceuticals, Inc. - White Paper Highlights Attributes of CBC

<div>
<div>
<div>
<div>
<ul>
<li>BayMedica’s exponential growth momentum continues.</li>
<li>This morning, InMed Pharmaceuticals (INM) provided a business update on the progress of its BayMedica subsidiary, a leading supplier of rare non- psychoactive cannabinoids to the health &amp; wellness sector.</li>
<li>In an early disclosure, ahead of a formal release of InMed’s 4QFY23 earnings, expected in September, the company signaled that BayMedica will report a 123% Q/Q increase in revenues to more than $2.3M for the fiscal fourth quarter ended June 30, 2023. </li>
</ul>
</div>
</div>
</div>
</div>






BayMedica’s exponential growth momentum continues.
This morning, InMed Pharmaceuticals (INM) provided a business update on the progress of its BayMedica subsidiary, a leading supplier of rare non- psychoactive cannabinoids to the health &amp; wellness sector.
In an early disclosure, ahead of a formal release of InMed’s 4QFY23 earnings, expected in September, the company signaled that BayMedica will report a 123% Q/Q increase in revenues to more than $2.3M for the fiscal fourth quarter ended June 30, 2023. 






InMed Pharmaceuticals, Inc. - Another Super BayMedica Quarter Signaled

<ul style="list-style-type: disc;"><li><p>The bottom line from the INM-755 Phase II study’s top-line results.</p></li><li><p>InMed published top-line data for its most advanced drug development program, INM-755, a cannabinol (CBN)-based topical skin cream to treat symptoms associated with a rare genetic dermatological condition called epidermolysis bullosa (EB).</p></li><li><p>Using a wide lens approach, the Phase II study produced sufficient clinically important chronic itch relief data to support a pathway to further development and potentially bigger commercial opportunities.</p></li></ul>

The bottom line from the INM-755 Phase II study’s top-line results.InMed published top-line data for its most advanced drug development program, INM-755, a cannabinol (CBN)-based topical skin cream to treat symptoms associated with a rare genetic dermatological condition called epidermolysis bullosa (EB).Using a wide lens approach, the Phase II study produced sufficient clinically important chronic itch relief data to support a pathway to further development and potentially bigger commercial opportunities.

UPDATE NOTE - InMed Pharmaceuticals, Inc. - July 6, 2023

Canada

InMed Pharmaceuticals Inc. is a biopharmaceutical company. The Company develops cannabis-based botanical and non-botanical therapies through research and development into the extensive pharmacology of cannabinoids. InMed Pharmaceuticals focuses on its proprietary platform technology, drug discovery, and commercialization development.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

InMed Pharmaceuticals (INM US)

InMed Pharmaceuticals Inc - Unveiling INM-901

InMed took a significant step forward in its INM-900 series program after confirming that it has made its final selection of a lead Alzheimer’s...

Water Tower Research

InMed Pharmaceuticals, Inc. - 4QFY23 Review; Progress on All Fronts

s had already been signaled in an early disclosure filing in July, InMed’s BayMedica subsidiary delivered $2.3 million of revenue for the final...

Water Tower Research

InMed Pharmaceuticals, Inc. - White Paper Highlights Attributes of CBC

InMed Pharmaceuticals’ commercial subsidiary BayMedica released a white paper, which collates a curated collection of scientific research

Water Tower Research

InMed Pharmaceuticals, Inc. - Another Super BayMedica Quarter Signaled

BayMedica’s exponential growth momentum continues. This morning, InMed Pharmaceuticals (INM) provided a business update on the progress of its...

Water Tower Research

UPDATE NOTE - InMed Pharmaceuticals, Inc. - July 6, 2023

Key takeaways from the INM-755 Phase II study. The data from 18 out of the study’s 19 enrolled participants were eligible for clinical review.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)